Applied Biologics' XWRAP hits wound closure endpoint in CAMPX trial
Applied Biologics has reported statistically significant improvements in wound closure from updated analyses of its ongoing CAMPX randomised controlled trial, evaluating placental-derived wound covering XWRAP in patients with chronic diabetic foot ulcers. The Scottsdale-based biopharmaceutical company said both its Intent-to-Treat and Per-Protocol analyses reached statistical significance, providing what it describes as a consistent picture of treatment benefit.
In the Intent-to-Treat population, 31% of patients treated with XWRAP alongside standard of care achieved complete wound closure, compared with 18% in the standard-of-care-only arm, an absolute difference of 13 percentage points (p=0.023). The Per-Protocol analysis produced a similar result: 33% versus 17%, representing a 16-percentage-point absolute improvement (p=0.039). The trial enrolled patients with both Wagner Grade 1 and Wagner Grade 2 ulcers across 23 SerenaGroup and affiliated research sites in the United States.
Trial design and investigator view
CAMPX is a prospective, multicentre, randomised controlled study conducted in collaboration with SerenaGroup, a wound care research organisation. Thomas Serena, founder of SerenaGroup and principal investigator on the trial, said the consistency of the findings across both populations was encouraging and that the inclusion of two Wagner Grade categories offered insight into real-world clinical outcomes. "The magnitude of the treatment effect observed among patients treated with XWRAP supports continued evaluation of this therapy in the management of chronic diabetic foot ulcers," he said.
Applied Biologics chief executive Edward Britt described the results as an important milestone but stopped short of making regulatory claims. The company noted that enrolment completion, database review, and final study closeout activities remain ongoing. Further analyses are planned following database lock, and the company intends to submit findings to a peer-reviewed journal.
Market context and competitive landscape
Chronic diabetic foot ulcers represent a substantial and persistent healthcare burden. The condition affects a significant proportion of people living with diabetes globally, and inadequate wound healing can lead to lower-limb amputation, making effective adjunctive therapies a long-standing clinical priority. The wound care biologics segment is populated by a number of established products, including living cell therapies and acellular dermal matrices from companies such as Organogenesis, MiMedx, and Integra LifeSciences, all of which have navigated the complex regulatory and reimbursement environment around advanced wound care.
Placental-derived allografts occupy a distinct niche within this landscape, positioned by developers as off-the-shelf biologics that avoid the manufacturing complexity associated with cellular products. Regulatory pathways for these products in the United States have attracted scrutiny from the FDA in recent years, with the agency moving to clarify its stance on human cells, tissues, and cellular and tissue-based products under its 361 HCT/P framework. Companies seeking broader commercial claims will typically require Biologics Licence Application approval, meaning the clinical data Applied Biologics is generating through CAMPX will be important in defining the regulatory route the company ultimately pursues.
The updated CAMPX data are encouraging for Applied Biologics at this stage of development, but clinicians and investors will reserve judgement until the final locked database is analysed and independent peer review is complete. The p-values reported sit above the 0.01 threshold that would constitute strong statistical evidence, and headline wound closure rates, without longer-term durability and safety data, provide only a partial picture of therapeutic value. Those fuller results, along with the company's stated intention to publish, will determine how the chronic wound care community ultimately receives XWRAP.